Skip to main content


Volume 11 Supplement 5

Severe sepsis and drotrecogin alfa (activated)


Edited by Antonio Artigas and Claude D Martin

Publication of the supplement has been sponsored by Eli Lilly & Company

  1. Content type: Review

    The burden of infection in industrialized countries has prompted considerable effort to improve the outcomes of patients with sepsis. This has been formalized through the Surviving Sepsis Campaign 'bundles', d...

    Authors: Yann-Erick Claessens and Jean-Fran├žois Dhainaut

    Citation: Critical Care 2007 11(Suppl 5):S2

    Published on:

  2. Content type: Review

    The predictive value of plasma protein C level in sepsis has been demonstrated in a number of studies in which depressed protein C levels were associated with increased likelihood of negative outcome. Data fro...

    Authors: Burkhard Vangerow, Andrew F Shorr, Duncan Wyncoll, Jonathan Janes, David R Nelson and Konrad Reinhart

    Citation: Critical Care 2007 11(Suppl 5):S4

    Published on:

  3. Content type: Review

    Continued safety assessment is essential for any newly approved therapy. Drotrecogin alfa (activated; DrotAA), which is approved for use in severe sepsis, has undergone clinical trials with corresponding safet...

    Authors: Roberto Fumagalli and Mariano A Mignini

    Citation: Critical Care 2007 11(Suppl 5):S6

    Published on: